CompletedNCT00272597
Switching to long-acting risperidone and healthcare use in psychosis
About this title
Read the official source — NCT00272597Medication studyAges 18–65CanadaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- CoquitlamSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- University of British Columbia
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00272597
- Official title
Show the full official title
Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Coquitlam
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of British Columbia, a university.
Did this study involve medication?
Yes. The study involved medication, including Risperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
